Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Nature

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Leukemia (26)
Blood Cancer Journal (20)
Nature Communications (8)
Bone Marrow Transplantation (3)
Nature Cancer (2)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (39)
Reviews (11)
Correspondence (9)
Amendments and Corrections (5)
Comments & Opinion (1)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Chemistry
Developmental biology
Diseases
Drug discovery
Genetics
Health care
Medical research
Oncology
Pathogenesis
Physics
Systems biology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–50 of 65 results

Advanced filters: Author: Elias Jabbour Clear advanced filters

Dasatinib

In June 2006, the tyrosine kinase inhibitor dasatinib (Sprycel; Bristol-Myers Squibb) was approved by the US FDA for the treatment of adults with chronic myeloid leukaemia and Philadelphia-chromosome-positive acute lymphoblastic leukaemia with resistance or intolerance to previous therapy, including the kinase inhibitor imatinib (Gleevec; Novartis).

Hagop Kantarjian
Elias Jabbour
Peter Kirkpatrick
Comments & Opinion01 Sept 2006
Nature Reviews Drug Discovery

Volume: 5, P: 717-718
Direct evidence of two interatomic relaxation mechanisms in argon dimers ionized by electron impact

Inter-particle reactions in weakly bound systems are often difficult to pinpoint by detecting exclusively the kinetic energy of the produced ions. Here the authors present a full-coincidence experiment, where inter-particle reaction channels are determined by the measurement of all outgoing particles.

Xueguang Ren
Elias Jabbour Al Maalouf
Stephan Denifl
ResearchOpen Access22 Mar 2016
Nature Communications

Volume: 7, P: 1-6
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL

Nicholas J. Short
Elias Jabbour
Hagop Kantarjian
ResearchOpen Access21 Oct 2025
Blood Cancer Journal

Volume: 15, P: 1-7
The clinical development of antibody–drug conjugates — lessons from leukaemia

Antibody–drug conjugates (ADCs) were originally developed for patients with haematological malignancies. In light of the recent increase in interest in this type of therapy, this Review describes the clinical experience with two ADCs — gemtuzumab ozogamicin and inotuzumab ozogamicin — in patients with haematological malignancies and provides guidance on the future directions for the development of novel ADCs for patients with leukaemias.

Elias Jabbour
Shilpa Paul
Hagop Kantarjian
Reviews23 Mar 2021
Nature Reviews Clinical Oncology

Volume: 18, P: 418-433
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Courtney D. DiNardo
Wei-Ying Jen
Hagop M. Kantarjian
Amendments and Corrections10 Dec 2025
Leukemia

Volume: 40, P: 262
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

DiNardo et al. perform a phase 1b/2 clinical trial of telaglenastat (CB-839) in combination with azacytidine in persons with advanced myelodysplastic syndromes and report on the treatment safety and efficacy, including a definition of clinical responders.

Courtney D. DiNardo
Divij Verma
Marina Konopleva
Research19 Sept 2024
Nature Cancer

Volume: 5, P: 1515-1533
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment

The effect of noncoding genetic variation on acute lymphoblastic leukemia treatment response is not fully understood. Here, the authors functionally evaluated variants associated with pharmacological traits and validate the role of rs1247117 in gene regulation impacting therapeutic response.

Kashi Raj Bhattarai
Robert J. Mobley
Daniel Savic
ResearchOpen Access01 May 2024
Nature Communications

Volume: 15, P: 1-14
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

Notch1 is frequently activated promoting T-cell acute lymphoblastic leukaemia (T-ALL). Here, the authors show that Notch1 induces oxidative phosphorylation dependency in T-ALL and synergism when inhibiting both mitochondrial complex I and glutaminolysis in preclinical murine and human xenograft models.

Natalia Baran
Alessia Lodi
Marina Konopleva
ResearchOpen Access19 May 2022
Nature Communications

Volume: 13, P: 1-20
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

A mitochondrial complex I inhibitor exhibited dose-limiting toxicities, including neurotoxicity, in patients with acute myeloid leukemia and solid tumors, warranting further studies to evaluate the mechanism linking oxidative phosphorylation inhibition and neurotoxicity.

Timothy A. Yap
Naval Daver
Marina Konopleva
Research19 Jan 2023
Nature Medicine

Volume: 29, P: 115-126
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

The regulation of resistance to IDH inhibitors in acute myeloid leukaemia is not completely understood. Here the authors reveal with integrative multi-omics analyses that stemness features are major drivers of primary resistance, while high-risk mutations drive acquired resistance.

Feng Wang
Kiyomi Morita
Koichi Takahashi
ResearchOpen Access10 May 2021
Nature Communications

Volume: 12, P: 1-13
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Jayastu Senapati
Muharrem Muftuoglu
Courtney D. DiNardo
ResearchOpen Access29 Jun 2023
Blood Cancer Journal

Volume: 13, P: 1-6
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Understanding the evolutionary trajectory of cancer samples may enable understanding resistance to treatment. Here, the authors used single cell sequencing of a cohort of acute myeloid leukemia tumours and identify features of linear and branching evolution in tumours.

Kiyomi Morita
Feng Wang
Koichi Takahashi
ResearchOpen Access21 Oct 2020
Nature Communications

Volume: 11, P: 1-17
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Aram Bidikian
Hagop Kantarjian
Ghayas C. Issa
ResearchOpen Access28 Oct 2022
Blood Cancer Journal

Volume: 12, P: 1-7
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome

Alexandre Bazinet
Guillermo Montalban-Bravo
Guillermo Garcia-Manero
Research05 Sept 2025
Leukemia

Volume: 39, P: 2820-2824
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

Musa Yilmaz
Feng Wang
Farhad Ravandi
ResearchOpen Access16 Jan 2019
Blood Cancer Journal

Volume: 9, P: 1-6
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

Yang and colleagues perform a network system–pharmacology approach and clinical data integration, and identify LCK and BCL2 signaling as the molecular determinants of dasatinib response in pediatric and adult patients with T-ALL.

Yoshihiro Gocho
Jingjing Liu
Jun J. Yang
Research21 Jan 2021
Nature Cancer

Volume: 2, P: 284-299
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax

Jennifer Croden
Wei-Ying Jen
Courtney D. DiNardo
Research14 Aug 2025
Leukemia

Volume: 39, P: 2538-2541
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements

Alex Bataller
Hannah E. Goulart
Elias Jabbour
Research09 May 2025
Leukemia

Volume: 39, P: 1640-1649
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Kiyomi Morita
Feng Wang
Koichi Takahashi
Amendments and CorrectionsOpen Access10 May 2021
Nature Communications

Volume: 12, P: 1
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy

Alexandre Bazinet
Sanam Loghavi
Guillermo Montalban-Bravo
Research21 Jul 2025
Leukemia

Volume: 39, P: 2256-2265
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Kiyomi Morita
Feng Wang
Koichi Takahashi
Amendments and CorrectionsOpen Access19 Nov 2020
Nature Communications

Volume: 11, P: 1
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Ian M. Bouligny
Guillermo Montalban-Bravo
Guillermo Garcia-Manero
Research17 Nov 2024
Leukemia

Volume: 39, P: 524-528
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes

Mixed phenotype acute leukemia (MPAL) is a rare leukemia that presents both myeloid and lymphoid markers on blasts. Here the authors perform genomic analysis to show MPAL involves genetic and epigenetic heterogeneity and is genetically distinct from AML, B-ALL, and T-ALL.

Koichi Takahashi
Feng Wang
P. Andrew Futreal
ResearchOpen Access10 Jul 2018
Nature Communications

Volume: 9, P: 1-12
Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

Guillermo Montalban-Bravo
Juan Jose Rodriguez-Sevilla
Guillermo Garcia-Manero
Research28 Feb 2024
Leukemia

Volume: 38, P: 1178-1181
Age-related prognoses of genetic subtypes in B-cell acute lymphoblastic leukemia/lymphoma (B-ALL): insights from a decade of national data

Ting Zhou
Nicholas J. Short
J. Bryan Iorgulescu
Research24 Apr 2025
Leukemia

Volume: 39, P: 1769-1772
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma

Farhad Ravandi
Jayastu Senapati
Hagop M. Kantarjian
Research25 Sept 2024
Leukemia

Volume: 38, P: 2717-2721
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study

Alex Bataller
Koji Sasaki
Guillermo Garcia-Manero
ResearchOpen Access31 Mar 2025
Blood Cancer Journal

Volume: 15, P: 1-9
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia

Courtney D. DiNardo
Wei-Ying Jen
Hagop M. Kantarjian
Research25 Feb 2025
Leukemia

Volume: 39, P: 854-863
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Guillermo Montalban-Bravo
Danielle Hammond
Guillermo Garcia-Manero
Research12 Apr 2021
Leukemia

Volume: 35, P: 1494-1499
Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib

Yuya Sasaki
Hagop M. Kantarjian
Elias Jabbour
Amendments and Corrections11 Apr 2022
Leukemia

Volume: 36, P: 1448
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Prithviraj Bose
Srdan Verstovsek
Farhad Ravandi
Research25 Feb 2020
Leukemia

Volume: 34, P: 2489-2492
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases

Mrinal M. Patnaik
Ana A. Pierola
Guillermo Garcia-Manero
Research25 Apr 2018
Leukemia

Volume: 32, P: 2512-2518
A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

Hui-Jen Tsai
Shih Sheng Jiang
Tsai-Yun Chen
ResearchOpen Access12 Sept 2017
Scientific Reports

Volume: 7, P: 1-10
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Elias Jabbour
Jane Apperley
Hagop Kantarjian
ResearchOpen Access29 Jan 2024
Leukemia

Volume: 38, P: 475-481
Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Hagop Kantarjian
Susan Branford
Francois Xavier-Mahon
Reviews26 Mar 2024
Leukemia

Volume: 38, P: 947-950
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia

Jayastu Senapati
Guillermo Garcia-Manero
Naval G. Daver
Correspondence11 Apr 2025
Bone Marrow Transplantation

Volume: 60, P: 910-913
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

Taha Al-Juhaishi
Yingjun Wang
Issa F. Khouri
Research18 May 2023
Bone Marrow Transplantation

Volume: 58, P: 1000-1007
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Mahesh Swaminathan
Courtney D. DiNardo
Marina Y. Konopleva
CorrespondenceOpen Access02 Apr 2025
Blood Cancer Journal

Volume: 15, P: 1-4
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Musa Yilmaz
Hagop Kantarjian
Naval Daver
ResearchOpen Access02 May 2022
Blood Cancer Journal

Volume: 12, P: 1-9
Variations in practices and outcomes of neonates with hypoxic ischemic encephalopathy treated with therapeutic hypothermia across tertiary NICUs in Canada

Marc Beltempo
Pia Wintermark
Andrzej Kajetanowicz
Research12 May 2022
Journal of Perinatology

Volume: 42, P: 898-906
Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib

Yuya Sasaki
Hagop M. Kantarjian
Elias Jabbour
Research07 Feb 2022
Leukemia

Volume: 36, P: 1253-1260
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Ghayas C. Issa
Jabra Zarka
Farhad Ravandi
ResearchOpen Access29 Sept 2021
Blood Cancer Journal

Volume: 11, P: 1-10
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations

Nitin Jain
Philip Thompson
William G. Wierda
Research18 May 2021
Leukemia

Volume: 35, P: 3421-3429
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Ghayas C. Issa
Hagop M. Kantarjian
Jorge E. Cortes
Research16 Jun 2020
Leukemia

Volume: 34, P: 2914-2924
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Nicholas J. Short
Hagop Kantarjian
Elias Jabbour
ResearchOpen Access26 May 2020
Blood Cancer Journal

Volume: 10, P: 1-9
High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma

Chi Young Ok
L. Jeffrey Medeiros
Sergej Konoplev
Research04 Sept 2018
Modern Pathology

Volume: 32, P: 48-58
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

Daniel J. DeAngelo
Anjali S. Advani
Susan O’Brien
ResearchOpen Access07 Aug 2020
Blood Cancer Journal

Volume: 10, P: 1-11
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Philip A. Thompson
Christine B. Peterson
William G. Wierda
Research17 Apr 2018
Leukemia

Volume: 32, P: 2388-2398
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Elias Jabbour
Jane Apperley
Hagop Kantarjian
Amendments and CorrectionsOpen Access02 Sept 2024
Leukemia

Volume: 38, P: 2291
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin

Jayastu Senapati
Elias Jabbour
Hagop M. Kantarjian
CorrespondenceOpen Access07 Aug 2024
Blood Cancer Journal

Volume: 14, P: 1-4

Previous page
page 1
page 2
Next page

Search

Search articles by subject, keyword or author

Show results from

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

Nature.com

nature.com sitemap

About Nature Portfolio

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
protocols.io
Nature Index

Publishing policies

Nature portfolio policies
Open access

Author & Researcher services

Reprints & permissions
Research data
Language editing
Scientific editing
Nature Masterclasses
Research Solutions

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Professional development

Nature Awards
Nature Careers
Nature Conferences

Regional websites

Nature Africa
Nature China
Nature India
Nature Japan
Nature Middle East

Privacy Policy
Use of cookies
Legal notice
Accessibility statement
Terms & Conditions
Your US state privacy rights

© 2026 Springer Nature Limited